• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's After-Market Session

    9/21/23 5:31:45 PM ET
    $BIAF
    $BWV
    $BXRX
    $CPHI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BIAF alert in real time by email

    Gainers

    • Regulus Therapeutics (NASDAQ:RGLS) stock increased by 12.4% to $1.45 during Thursday's after-market session. The company's market cap stands at $28.2 million.
    • SeqLL (NASDAQ:SQL) shares moved upwards by 10.34% to $15.79. The company's market cap stands at $6.0 million.
    • bioAffinity Technologies (NASDAQ:BIAF) shares moved upwards by 9.43% to $1.16. The market value of their outstanding shares is at $10.1 million.
    • Enveric Biosciences (NASDAQ:ENVB) shares increased by 9.05% to $2.65. The market value of their outstanding shares is at $5.7 million.
    • Blue Water Biotech (NASDAQ:BWV) shares rose 8.67% to $0.61. Trading volume for this security closed at 129.4K, accounting for 130.5% of its average full-day volume over the last 100 days. The company's market cap stands at $9.7 million.
    • China Pharma Holding (AMEX:CPHI) stock rose 7.01% to $0.14. At the close, China Pharma Holding's trading volume reached 65.8K shares. This is 7.2% of its average volume over the last 100 days. The company's market cap stands at $1.6 million.

    Losers

    • Baudax Bio (NASDAQ:BXRX) shares decreased by 10.1% to $0.31 during Thursday's after-market session. The market value of their outstanding shares is at $2.8 million.
    • Surrozen (NASDAQ:SRZN) stock declined by 6.49% to $0.43. The market value of their outstanding shares is at $13.0 million.
    • TransCode Therapeutics (NASDAQ:RNAZ) stock decreased by 6.45% to $0.65. Today's trading volume for this security ended up closing at 583.3K shares, which is 103.7 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $1.3 million.
    • IGC Pharma (AMEX:IGC) stock fell 5.33% to $0.37. The market value of their outstanding shares is at $19.9 million.
    • Taysha Gene Therapies (NASDAQ:TSHA) stock declined by 4.63% to $2.89. The market value of their outstanding shares is at $540.3 million.
    • TRACON Pharma (NASDAQ:TCON) stock decreased by 4.57% to $0.21. The market value of their outstanding shares is at $6.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BIAF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIAF
    $BWV
    $BXRX
    $CPHI

    CompanyDatePrice TargetRatingAnalyst
    Surrozen Inc.
    $SRZN
    2/19/2026$40.00Overweight
    Cantor Fitzgerald
    Taysha Gene Therapies Inc.
    $TSHA
    10/21/2025$13.00Strong Buy
    Raymond James
    Taysha Gene Therapies Inc.
    $TSHA
    7/11/2025$8.00Buy
    BofA Securities
    Regulus Therapeutics Inc.
    $RGLS
    3/27/2025$3.00 → $6.00Equal Weight → Overweight
    Wells Fargo
    Surrozen Inc.
    $SRZN
    1/30/2025$32.00Buy
    H.C. Wainwright
    Surrozen Inc.
    $SRZN
    1/3/2025$45.00Neutral → Buy
    Guggenheim
    Regulus Therapeutics Inc.
    $RGLS
    8/2/2024$7.00Outperform
    Oppenheimer
    Taysha Gene Therapies Inc.
    $TSHA
    6/27/2024$5.00Outperform
    BMO Capital Markets
    More analyst ratings

    $BIAF
    $BWV
    $BXRX
    $CPHI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tcg Crossover Gp Ii, Llc bought $1,220,362 worth of shares (48,997 units at $24.91) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    3/16/26 7:05:51 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Tcg Crossover Gp Ii, Llc bought $444,844 worth of shares (18,856 units at $23.59) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    2/13/26 4:19:53 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Tcg Crossover Gp Ii, Llc bought $202,534 worth of shares (9,357 units at $21.65) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    2/3/26 8:03:54 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIAF
    $BWV
    $BXRX
    $CPHI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Surrozen with a new price target

    Cantor Fitzgerald initiated coverage of Surrozen with a rating of Overweight and set a new price target of $40.00

    2/19/26 7:52:22 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Raymond James initiated coverage on Taysha Gene Therapies with a new price target

    Raymond James initiated coverage of Taysha Gene Therapies with a rating of Strong Buy and set a new price target of $13.00

    10/21/25 7:22:35 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BofA Securities initiated coverage on Taysha Gene Therapies with a new price target

    BofA Securities initiated coverage of Taysha Gene Therapies with a rating of Buy and set a new price target of $8.00

    7/11/25 8:16:08 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIAF
    $BWV
    $BXRX
    $CPHI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Expect to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Scheduled to present retinal vascular research on SZN-8141 at the upcoming 2026 ARVO Annual Meeting Received notice of achievement of research milestone by Boehringer Ingelheim for SZN-413, triggering $5 million milestone payment Strengthened key leadership roles in 2025 to support long-term ophthalmology strategy SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-t

    3/23/26 4:05:00 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update

    Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026 Received FDA clearance to initiate ASPIRE trial in three patients aged 2 to <4 years with inclusion of ≥3 months of safety data in planned BLA submission to support potential for broad label; on track to complete dosing in Q2 2026 Maintained favorable tolerability profile with no treatment-related SAEs or DLTs in REVEAL Phase 1/2 and REVEAL pivotal trials as of March 2026 data cutoff; longer-term safety and efficacy data from Part A of REVEAL Phase 1/2 trials expected in Q2 2026 Reached written alignment with FDA on proposed PPQ

    3/19/26 8:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Enveric Biosciences Announces Registration of Five Trademarks

    Canadian Trademark Office Issues House Marks to Enveric Biosciences, Inc. Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the Canadian Intellectual Property Office has registered five of the Company's trademarks, including its house marks, Enveric and Enveric Biosciences. "The registration of a Company's house marks, such as our marks Enveric and Enveric Biosciences, is an important intellectual property milestone supporting our branding strategies for our future products. We thank the Canadian Intellectual Property

    3/18/26 8:00:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIAF
    $BWV
    $BXRX
    $CPHI
    SEC Filings

    View All

    SEC Form S-8 filed by Surrozen Inc.

    S-8 - Surrozen, Inc./DE (0001824893) (Filer)

    3/23/26 5:26:31 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-3 filed by Surrozen Inc.

    S-3 - Surrozen, Inc./DE (0001824893) (Filer)

    3/23/26 5:26:03 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Surrozen Inc.

    10-K - Surrozen, Inc./DE (0001824893) (Filer)

    3/23/26 4:30:03 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIAF
    $BWV
    $BXRX
    $CPHI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tcg Crossover Gp Ii, Llc bought $1,220,362 worth of shares (48,997 units at $24.91) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    3/16/26 7:05:51 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Exec. Vice President, Research Li Yang

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    2/18/26 6:47:26 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Operating Officer Williams Charles O

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    2/18/26 6:45:04 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIAF
    $BWV
    $BXRX
    $CPHI
    Leadership Updates

    Live Leadership Updates

    View All

    bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board

    Advisory Board provides independent guidance on strategic priorities, including growing adoption of the Company's noninvasive CyPath® Lung diagnostic test bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced new appointments to its Medical and Scientific Advisory Board, welcoming David Ost, MD, MPH, University of Texas MD Anderson Cancer Center, Daniel Sterman, MD, New York University Langone Medical Center, and J. Scott Ferguson, MD, University of Wisconsin School of Medicine and Public Health, to its panel of recognized leaders in the field. The appointments reflect a planned expans

    2/9/26 8:00:00 AM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ENvue Medical Appoints Veteran Healthcare-Industry Executive, David Johnson, as Chairman

    ENvue Medical, Inc. (NASDAQ:FEED) ("ENvue" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced the appointment of David Johnson as Chairman of the Board. Mr. Johnson will work alongside CEO, Doron Besser, and the existing leadership team. David Johnson, newly appointed Chairman of ENvue, stated, "We believe ENvue is at the forefront of advanced feeding-tube placement technology, which has been validated in the market and extensively used in the clinic across 38 hospitals in the US. In my opinion, the Company's unique feeding tube placement system that utilizes advanced methods of navigation, integrated sensors and body mapping h

    12/15/25 9:00:00 AM ET
    $ENVB
    $FEED
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    $BIAF
    $BWV
    $BXRX
    $CPHI
    Financials

    Live finance-specific insights

    View All

    Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update

    Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026 Received FDA clearance to initiate ASPIRE trial in three patients aged 2 to <4 years with inclusion of ≥3 months of safety data in planned BLA submission to support potential for broad label; on track to complete dosing in Q2 2026 Maintained favorable tolerability profile with no treatment-related SAEs or DLTs in REVEAL Phase 1/2 and REVEAL pivotal trials as of March 2026 data cutoff; longer-term safety and efficacy data from Part A of REVEAL Phase 1/2 trials expected in Q2 2026 Reached written alignment with FDA on proposed PPQ

    3/19/26 8:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19

    DALLAS, March 12, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2025, and host a corporate update conference call and webcast on Thursday, March 19, 2026, at 8:30 AM Eastern Time. Participants may access the live webcast of the conference call from the Events and Presentations page of Taysha's website at ir.tayshagtx.com. An archived replay of the webcast will be available on

    3/12/26 8:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    TSHA-102 granted Breakthrough Therapy designation by FDA Finalized FDA alignment on REVEAL pivotal trial protocol and SAP, including 6-month interim analysis that may expedite BLA submission, which was enabled by the rigorous developmental milestone evaluation in Part A REVEAL Phase 1/2 trials showing an unprecedented response rate Dosing of first patient in REVEAL pivotal trial scheduled for Q4 2025, with enrollment of additional patients expected to continue at multiple sites this quarter Presented new supplemental analysis of Part A REVEAL data reinforcing the broad and consistent, multi-domain impact of TSHA-102 on activities of daily living at the CNS Annual Meeting TSHA-102

    11/4/25 7:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIAF
    $BWV
    $BXRX
    $CPHI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc.

    SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)

    11/14/24 8:51:58 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Taysha Gene Therapies Inc.

    SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)

    11/14/24 5:51:11 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Taysha Gene Therapies Inc.

    SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)

    11/14/24 5:46:12 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care